{"symbol":"ABT","provider":"yahoo-finance","fetchedAt":"2025-12-24T18:21:39.300Z","asOfDate":"2025-12-24","articles":[{"id":"680ea202-a397-30cd-8cd1-2f1b5a836a07","title":"How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?","url":"https://finance.yahoo.com/news/well-boston-scientific-placed-long-134000022.html","publisher":"Zacks","publishedAt":"2025-12-24T13:40:00.000Z","relatedTickers":["BSX","EW"],"mainIdea":"How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?","summary":"Zacks: How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?. BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market. Related tickers mentioned: BSX, EW."},{"id":"97bd51f2-3949-33f4-a12b-1f41ad8be31e","title":"Is Fidelity Medical Equipment the Ultimate \"Forever Fund\" for Health Care Investors?","url":"https://finance.yahoo.com/m/97bd51f2-3949-33f4-a12b-1f41ad8be31e/is-fidelity-medical-equipment.html","publisher":"Motley Fool","publishedAt":"2025-12-24T13:05:00.000Z","relatedTickers":["XLV"],"mainIdea":"Is Fidelity Medical Equipment the Ultimate \"Forever Fund\" for Health Care Investors?","summary":"Motley Fool: Is Fidelity Medical Equipment the Ultimate \"Forever Fund\" for Health Care Investors?. This basket of 64 medical device stocks could raise its dividend for decades. Related tickers mentioned: XLV."},{"id":"63ee0fbd-cdbd-33b4-8b57-e8f5deb2e4ce","title":"Abbott Stock May Benefit Following Volt PFA's FDA Approval","url":"https://finance.yahoo.com/news/abbott-stock-may-benefit-following-190800413.html","publisher":"Zacks","publishedAt":"2025-12-23T19:08:00.000Z","relatedTickers":[],"mainIdea":"Abbott Stock May Benefit Following Volt PFA's FDA Approval","summary":"Zacks: Abbott Stock May Benefit Following Volt PFA's FDA Approval. ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance."},{"id":"3c2d7175-535b-38cb-afb2-3450fcd6176e","title":"Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?","url":"https://finance.yahoo.com/news/abbott-laboratories-attractively-priced-recent-171130725.html","publisher":"Simply Wall St.","publishedAt":"2025-12-23T17:11:30.000Z","relatedTickers":[],"mainIdea":"Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?","summary":"Simply Wall St.: Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?. If you have been wondering whether Abbott Laboratories is still a buy at around $125 a share, you are not alone. This is exactly the kind of stock where valuation really matters. Despite slipping about 2.5% over the last week and 2.3% over the past month, Abbott is still up 10.4% year to date and roughly 11.6% over the last year, which keeps it firmly on investors radar as a steady compounder. Recent attention on Abbott has centered on its medical devices and diagnostics businesses,..."},{"id":"d135979f-2f2e-3d34-8c21-ead313a82e7d","title":"This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?","url":"https://finance.yahoo.com/m/d135979f-2f2e-3d34-8c21-ead313a82e7d/this-dividend-stock-just.html","publisher":"Barchart","publishedAt":"2025-12-23T16:45:53.000Z","relatedTickers":[],"mainIdea":"This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?","summary":"Barchart: This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?. Abbottâ€™s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?"}]}
